The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
 
Erika P. Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Timothy J. Pluard
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Carrick Therapeutics; Daiichi Sankyo/Astra Zeneca; DualityBio; Gilead Sciences; Jazz Pharmaceuticals; Kestrel Therapeutics; Merck; Novartis; Pfizer; Scorpion Therapeutics; Seagen; Sermonix Pharmaceuticals; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Gilead Sciences; SeaGen; Stemline Therapeutics
Research Funding - Arvinas; AstraZeneca/Daiichi Sankyo (Inst); Dantari (Inst); G1 Therapeutics (Inst); H3 Biomedicine (Inst); HiberCell (Inst); Novartis; Novartis; Olema Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); Sanofi (Inst); Scorpion Therapeutics; Seagen (Inst); Zymeworks (Inst)
 
Judy S. Wang
Consulting or Advisory Role - Fusion Pharmaceuticals; Kanaph Therapeutics
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Health (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biostar (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene (Inst); Centessa Pharmaceuticals (Inst); Coherus Biosciences (Inst); Compugen (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Medikine (Inst); Merck (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Nurix (Inst); Olema Oncology (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Aki Morikawa
Consulting or Advisory Role - Eisai; Lilly; Seagen
Research Funding - Dantari Pharmaceuticals (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); F. Hoffmann LaRoche (Inst); Freenome (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck Sharp & Dohme Corp. (Inst); Merrimack (Inst); Millenium Pharamceuticals (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Suzhou Zanrong Pharma (Inst); Tempus (Inst)
Other Relationship - Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Puma Biotechnology
 
Stephen R. D. Johnston
Honoraria - AstraZeneca; Lilly; Pfizer
Consulting or Advisory Role - Genzyme; Lilly; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst)
Expert Testimony - Novartis
 
Elizabeth Claire Dees
Consulting or Advisory Role - Novartis (I); Sanofi
Research Funding - Boehringer Ingelheim; G1 Therapeutics; H3 Biomedicine; Meryx Pharmaceuticals; Pfizer
 
Christos Vaklavas
Employment - Flatiron Health (I)
Honoraria - Cardinal Health; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Guidepoint Global; Novartis; Pfizer; Pfizer; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences
Research Funding - AstraZeneca (Inst); AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); H3 Biomedicine (Inst); Incyte (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); TRACON Pharma (Inst); Zymeworks (Inst)
Other Relationship - Daiichi Sankyo; Puma Biotechnology; Takeda
(OPTIONAL) Uncompensated Relationships - Genentech
 
Anne C. Armstrong
Stock and Other Ownership Interests - AstraZeneca (I)
Consulting or Advisory Role - Gilead Sciences; MSD; Roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; MSD Oncology; Novartis; Roche
Other Relationship - Gilead Sciences (Inst)
 
Pamela N. Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal
Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; NIH/NCI
 
Nisha Unni
Honoraria - M3
Consulting or Advisory Role - bioTheranostics; Pfizer
 
Gail Lynn Shaw Wright
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai/H3 Biomedicine (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Hutchison MediPharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); NanoString Technologies (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Oncothyreon (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Fadi Kayali
No Relationships to Disclose
 
Tingting Song
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Yuanxin Rong
Employment - Eisai
 
Kohei Yamaguchi
Employment - Eisai
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Lilly; MapKure; Novartis; Pfizer; PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Scorpion Therapeutics; Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)